RE:RE:RE:This thread as become my new site for entertainment Lol. Well, comparing xB3 to a drug means little. xB3 delivers drugs. Your "short" opinion shows that you don't understand the difference between a drug and a means of delivering a drug. Except for undisclosed new drugs that partners might be working on, the Bioasis payloads are known drugs. Herceptin has been in use for over 20 years because it works. As BT2111, it worked in those Texas mice.
xB3 has succeeded at every delivery it's been asked to do.
Overall, it has turned out that the reason for shorting Bioasis has been the management. Since the company was started the plan was to sell Bioasis and to never take a clinical chance with it. It was Mark Day who wanted to go clinical, a plan that finally got implemented by DrDR.
I understand the lack of Bioasis promotion and lack of corporate enthusiasm, but the company appears to nevertheless be getting a lot of preclinical studies done, both internally and with partners.
You gotta bone up on this play before you offer comments like that, darnit.
jd